Peptides for Cardiovascular
Overview
8 research peptides are currently studied for cardiovascular. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Semaglutide — FDA Approved
Evidence Rating: A Category: Metabolic / GLP-1 Agonist
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1. It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). Developed by Novo Nordisk and first...
Key claims: Causes significant weight loss; Improves blood sugar control.
Liraglutide — FDA Approved
Evidence Rating: A Category: Metabolic / GLP-1 Agonist
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was the first GLP-1 agonist approved for obesity. While effect...
Key claims: Clinically significant weight loss; Improves glycemic control.
Dulaglutide — FDA Approved
Evidence Rating: A Category: Metabolic / GLP-1 Agonist
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. It is a fusion protein consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a small peptide linker (MW ~59,670 g/m...
Key claims: Effective glycemic control in type 2 diabetes; Produces clinically meaningful weight loss.
Albiglutide — FDA Approved
Evidence Rating: A Category: Metabolic / GLP-1 Agonist
Albiglutide (brand name Tanzeum in the US, Eperzan in Europe) was a once-weekly GLP-1 receptor agonist consisting of two copies of a modified GLP-1 sequence fused to human albumin (MW ~72,970 g/mol). Developed by GlaxoSmithKline, it was FDA-approved in April 2014 for type 2 diabetes. GSK voluntarily...
Key claims: Reduces HbA1c in type 2 diabetes; Reduces major adverse cardiovascular events.
Cardiogen — Animal/Preclinical Only
Evidence Rating: D Category: Cardiovascular / Anti-Aging
Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide (MW ~489.5 g/mol) from the Khavinson bioregulatory peptide family, proposed as a cardiac-specific peptide for myocardial regeneration and cardiovascular aging. It is claimed to modulate gene expression in cardiomyocytes, improving contrac...
Key claims: Improves cardiac function in elderly; Reduces age-related cardiac fibrosis.
Vesilute — Animal/Preclinical Only
Evidence Rating: D Category: Cardiovascular / Anti-Aging
Vesilute (Lys-Glu-Asp, KED) is a synthetic tripeptide (MW ~390.4 g/mol) from the Khavinson bioregulatory peptide family, developed as a vascular-specific bioregulator. It is proposed to restore endothelial function, reduce atherosclerotic changes, and improve vascular elasticity in aging. Published ...
Key claims: Improves vascular function in aging; Reduces endothelial dysfunction.
B7-33 — Preclinical Only
Evidence Rating: D Category: Cardiovascular / Research
B7-33 is a simplified, single-chain analog of human relaxin-2, designed to retain RXFP1 receptor activation while being easier and cheaper to manufacture than the native two-chain hormone. It shows vasodilatory and anti-fibrotic properties in preclinical models.
Key claims: Cardiovascular protection; Anti-fibrotic effects.
Vesugen — Limited Evidence
Evidence Rating: D Category: Cardiovascular / Bioregulator
Vesugen (Lys-Glu-Asp) is a synthetic tripeptide from the Khavinson bioregulator series designed to normalize vascular endothelial function through tissue-specific gene regulation.
Key claims: Vascular health improvement.
Related Products
Semaglutide 10mg
10mg
Related Research News
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.